Side-by-side comparison of AI visibility scores, market position, and capabilities
Booking Holdings OTA known for Express Deals opaque hotel discounts; US market focus within the $21B Booking Holdings portfolio competing with Expedia for budget travelers.
Priceline is an online travel agency (OTA) known for its opaque pricing models and deep discount positioning — pioneering the "Name Your Own Price" bidding system for hotels and flights in the late 1990s, and now one of the largest OTAs globally with additional brands including Booking.com, Kayak, Agoda, OpenTable, and Rentalcars.com under parent company Booking Holdings (NASDAQ: BKNG). Priceline generates billions in revenue as part of the Booking Holdings portfolio, which collectively produces approximately $21 billion in annual revenue.\n\nPriceline's platform offers hotel bookings, flight reservations, rental car reservations, vacation packages, and cruise bookings at negotiated rates. The Express Deals product (rebrand of the opaque pricing model) offers significantly discounted hotel rates where the specific hotel is revealed after booking — enabling hotels to offer steeper discounts without damaging their public rate card. The brand has diversified beyond opaque pricing to include standard transparent hotel and flight booking as well as package deals and the Priceline VIP program for frequent bookers.\n\nIn 2025, Priceline operates within Booking Holdings' portfolio alongside Booking.com (the dominant European and global hotel OTA), which generates the majority of the group's revenue. Priceline competes with Expedia (Hotels.com, Vrbo), Tripadvisor, and direct hotel booking channels for US leisure and business travelers. The OTA market faces ongoing tension with hotel chains (Marriott, Hilton, IHG) that incentivize direct booking with loyalty point bonuses and rate-match guarantees. Booking Holdings' 2025 strategy for Priceline focuses on the US market where Booking.com has less penetration, growing the package and cruise businesses, and deepening AI-powered trip planning tools that provide travel inspiration alongside booking functionality.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.